| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | GSK1120212 | CTRPv2 | pan-cancer | AAC | -0.028 | 0.6 |
| mRNA | vorinostat:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | -0.03 | 0.6 |
| mRNA | BRD-K48477130 | CTRPv2 | pan-cancer | AAC | -0.032 | 0.6 |
| mRNA | LRRK2-IN-1 | CTRPv2 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | WZ8040 | CTRPv2 | pan-cancer | AAC | -0.022 | 0.6 |
| mRNA | BRD-K51831558 | CTRPv2 | pan-cancer | AAC | -0.03 | 0.6 |
| mRNA | ML203 | CTRPv2 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | Compound 23 citrate | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | ML162 | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |